Результаты поиска

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.

Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and … and arthritis. Sex-, age-, and weight-related differences were noted for dulaglutide, liraglutide, semaglutide, sitagliptin, linagliptin, alogliptin, and saxagliptin. Median onset was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days), with vildagliptin latest. Weibull analysis indicated an early-failure pattern for most a …

Glucagon-like Peptide-1 Receptor Agonists and Chronic Pain: Preclinical Antinociceptive Mechanisms, Indirect Metabolic-Functional Effects, and Clinical Considerations-A Narrative Review.

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly encountered in pain practice, but reported pain … In STEP 9 (n = 407), mean WOMAC pain scores at 68 weeks changed from baseline by -41.7 points with semaglutide 2.4 mg and -27.5 points with a placebo; body weight changed by -13.7% and -3.2%, respectively. Liraglutide produced additional weight loss without superior knee-pain reduction. Diabetic peripheral neuropathy evidence was mainly structural or neuroph …

Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.

BackgroundLimited studies to date have yielded inconsistent results regarding the association between glucagon-like peptide-1 receptor agoni … 59; P < 0.001). This trend was consistently observed across individual GLP-1RA molecules, including semaglutide (PRR, 0.45; 95% CI, 0.39 to 0.51), dulaglutide (PRR, 0.49; 95% CI, 0.45 to 0.54), and liraglutide (PRR, 0.30; 95% CI, 0.26 to 0.35). These results remained robust after conducting secondary and sensitivity analyses, further supporting their consiste …

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

OBJECTIVE: To compare the efficacy and safety of glucagon-like peptide 1 (GLP-1) based drug treatments for weight loss in adults with overwe … owed by tirzepatide (-19.28%, -20.39% to -18.16%), and CagriSema (a combination of cagrilintide and semaglutide, -17.32%, -19.32% to -15.32%). Conventional GLP-1 receptor agonists showed more modest effects. Similar patterns were seen for waist circumference and lipid outcomes. Treatment rankings suggested a probabilistic hierarchy favouring next generation i …

Осложнения периферального нерва в результате применения лекарств для потери веса: систематический обзор.

ЦЕНТРАЛЬНАЯ ИНФОРМАЦИЯ: Существует глобальная эпидемия ожирения, и в этом контексте разработка новых агентов для снижения веса является своевременной. Поступали сообщения о периферийных осложнениях нервной системы, и это исследование было направлено на систематический анализ всех сообщенных случаев, связанных с лекарственными препаратами, используемыми для снижения веса. МЕТОДЫ: Был проведен систематический поиск баз данных PubMed, Embase и CINAHL с момента создания по 30 июня 2026 года в целях выявления исследований, в которых сообщается о новых или ухудшающихся периферийных осложнениях нервн

Совпадение в аннотации оригинала
BACKGROUND: There is a global epidemic of obesity and in this context, the development of novel agents for weight loss has been timely. Ther … t. Median rate of weight loss was 3.7 kg/month (IQR 1.7), with symptom onset at 150 days (IQR 135). Semaglutide or tirzepatide were implicated in the majority (83%), and 67% had pre-diabetes/diabetes. Neurological presentations included fibular neuropathy (n = 10), lumbosacral radiculoplexus neuropathy (n = 9) and distal symmetric polyneuropathy (n = 7). Elec …

Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.

Incretin-based therapies have transformed the management of obesity and type 2 diabetes mellitus (T2DM). Established agents-the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide-are now widely used, while a diverse pipeline of multi-receptor agents is advancing through late-phase development. GLP-1 receptors are expressed in several oral and other craniofacial tissues, raising the question of how these drugs affect oral health. This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, Cl…

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

AIMS: This meta-analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) i … without background medications. RESULTS: 62 studies utilising dulaglutide, exenatide, liraglutide, semaglutide, beinaglutide, retatrutide, or tirzepatide, with 66,232 patients, mean age of 58.3 years (14.4 to 68), and mean follow-up of 43.5 weeks (1 to 198) were included in this study. Meta-analysis showed a significantly increased risk of pancreatitis (RR: …

Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.

The effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug-dose combinations of GLP-1RAs on SBP. The secondary aim was to assess whether changes in SBP with GLP-1RAs are associated with weight change. MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP. Separate analyses were done for tri…

Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.

BACKGROUND: Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight … tric bypass) whereas it was reduced roughly by half with GLP-1RA therapy (five studies, mainly with semaglutide). Similar findings were reported with other addictive disorders. An addiction transfer from food addiction to other addictive disorders is hypothesized to explain the increased risk after bariatric surgery. Several mechanisms are proposed to explain …

The intricate relationship between circadian rhythms and gastrointestinal peptides in obesity.

There are different molecular pathways that regulate appetite, particularly the role of the hypothalamus, circadian rhythms, and gastrointes … re these pathways in obesity management, especially with the rise of incretin-based treatments like semaglutide. A deeper understanding of hypothalamic molecular mechanisms could lead to novel pharmacological and non-pharmacological therapies for obesity.

Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for their efficacy in glycemic control and weight reduction, but patient response is heterogeneous and predictors of weight loss remain insufficiently defined. This 52-week prospective, observational study aimed to identify predictors of weight reduction (≥5% from baseline) in patients with type 2 diabetes mellitus (T2D) undergoing GLP-1RA therapy (semaglutide or dulaglutide, including oral formulations). METHODS: A total of 194 adults with T2D initiating GLP-1RA therapy were evaluated at baseline, and af…

Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis.

Glucagon-like-peptide-1 (GLP-1) agonists are commonly used to improve glycemic control and promote weight loss in individuals with type 2 diabetes mellitus (T2DM) and/or obesity. However, there is a paucity of evidence regarding GLP-1 agonist use in people with cystic fibrosis (pwCF). We present 11 people with CF (males: 3, females: 7; age range 24-47; BMI range 25.7-43.7) treated with GLP-1 agonists (semaglutide: 9,tirzepatide: 2) for variable duration (1-50 months). All experienced weight loss on GLP- 1 agonist therapy (median change in weight = -7.2 kg; change in BMI [kg/m2] = -0.9 to -8.1)…

Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis.

BACKGROUND: Non-alcoholic steatohepatitis (NASH), a chronic liver disease, has no United States Food and Drug Administration (FDA) approved … the most tested drugs being the FXR agonist EDP-305 and the Glucagon-like peptide-1 (GLP-1) agonist semaglutide. CONCLUSION: Old drugs are further repurposed for testing in NASH treatment, novel drugs are developed to try to cure NASH. We expect that the drug clinical trials will accelerate the frontier of therapeutic development in NASH, bring an innovative …

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.

AIM: Glucagon-like peptide-1 receptor agonists provide multiple benefits to patients with type 2 diabetes, including improved glycaemic cont … alysis) to provide primary data for our ongoing pharmacogenomic study of pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative assessments of the effects of glucagon-like peptide-1 receptor agonists on glucose metabolism: first phase insulin secretion, glucose disappearance rates and glucose effectiveness.

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.

CONTEXT: The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in the United States. This c … arlier trials, has been confirmed in adults with biopsy-proven NASH. In 2021, the FDA also approved semaglutide for obesity management. CONCLUSION: A paradigm change is developing between the endocrinologist's greater awareness about their critical role to curve the epidemic of NAFLD and new clinical care pathways that include a broader use of GLP-1RAs in th …

Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.

GLP-1 analogs suffer from the main disadvantage of a short in vivo half-life. Lithocholic acid (LCA), one of the four main bile acids in the … In db/ db mice, 5b exhibited comparable hypoglycemic and insulinotropic activity to liraglutide and semaglutide. Importantly, the enhanced albumin affinity of 5b resulted in a prolonged in vivo antidiabetic duration. Finally, chronic treatment investigations of 5b demonstrated the therapeutic effects of 5b on HbA1c, body weight, blood glucose, and pancreatic …

Gut-brain axis in Alzheimer's disease: neuroinflammatory mechanisms and immunopharmacological interventions.

Despite being defined pathologically by amyloid-β plaques, chronic neuroinflammation and neurofibrillary tangles, the drugs that target thes … isconnect between mechanistic promise and clinical efficacy, including a definitive null result for semaglutide in 2026. Translative directions are addressed to nanotechnology-based delivery systems for improving bioavailability and blood-brain barrier penetration, as well as emerging precision-medicine, AI-driven approaches in the selection of treatments bas …

How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials.

Across the full spectrum of major clinical trials evaluating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management, nausea consistently emerges as the most documented adverse effect, yet the methods used to capture it have received little scrutiny relative to their clinical importance. This narrative review traces how nausea was actually measured across the pivotal liraglutide (SCALE), semaglutide (STEP) and tirzepatide (SURMOUNT) obesity trial programmes, and situates those methods against the standards set out in the Consensus-based Standards for the selection of healt…

Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.

BACKGROUND/OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have an exciting future potential beyond metabolic disorders. Thi … mized controlled trials (RCTs) provided contradictory outcomes (p = 0.37; 29% reduction, p = 0.04). Semaglutide reduced the risk of tobacco use disorder (HR 0.68; 95% CI 0.630.74). There was a great decrease in the risk of opioid overdose (HR 0.32-0.58). The incidence (HR 0.86), mortality (HR 0.50), and suicidal ideation were less in composite substance use d …

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes mellitus (T2DM) and obesity, but concerns abo … one of the 11 included studies directly measured mood using validated questionnaires and found that semaglutide was associated with lower (better) depression and anxiety scores. GLP-1 receptor agonists appear to maintain a safe neuropsychiatric profile, with an emerging signal that mood may benefit, currently limited to a single scale-based study among those …